Table 2 Clinical Characteristics of the Study Samples
From: Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
ranibizumab (Lucentis®) | bevacizumab (Avastin®) | |
|---|---|---|
Endothelial Cell Density ECD [Cells/mm2] | ||
Before Treatment (Mean [Range]) | 2441 [1700;3200] | 2234 [1700;2800] |
After Treatment 0 μg/ml (control) | 1847 | 1644 |
After Treatment 2.5 μg/ml | 1511 | 1587 |
After Treatment 25 μg/ml | 1460 | 1417 |
After Treatment 250 μg/ml | 1715 | 1352 |
Cell loss 0 μg/ml (control) | 18.1% | 15.8% |
Cell loss 2.5 μg/ml | 22.5% | 18.0% |
Cell loss 25 μg/ml | 25.7% | 25.8% |
Cell loss 250 μg/ml | 24.2% | 32.5% |
Corneal Area [mm2] (Mean) | 75.0 | 67.0 |